Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program:

Charung Muangchana1, Narong Henprasertthae, Krissana Nurach

  • 1National Vaccine Institute (NVI), Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. charungm@hotmail.com

Vaccine
|November 15, 2011
PubMed

Insights

The mouse brain-derived Japanese encephalitis vaccine (MB JEV) is highly effective in preventing Japanese encephalitis (JE) in children. Aggressive immunization programs utilizing MB JEV can significantly reduce the disease burden.

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • The mouse brain-derived Japanese encephalitis vaccine (MB JEV) has been part of Thailand's National Immunization Program (NIP) since 1990.
  • Concerns regarding MB JEV effectiveness arose due to recent studies reporting 30-40% of Japanese encephalitis (JE) cases occurred in vaccinated individuals.

Purpose of the Study:

  • To assess the effectiveness of the MB JEV used in the Thai NIP among children aged 1 to <6 years.
  • To provide evidence-based recommendations for JE vaccination strategies in Thailand.

Main Methods:

  • A case-control study was conducted in 2010, enrolling 26 laboratory-confirmed JE cases and 103 age- and community-matched controls.
  • Immunization status was verified using individual health records.
  • Effectiveness was calculated for children aged ≥ 18 months, the NIP's recommended age.

Main Results:

  • The estimated effectiveness of MB JEV among children aged ≥ 18 months was 94.6% (95% CI, 79.6-98.6%).
  • Adjusted effectiveness reached 97.50% (95% CI, 88.60-99.50%).
  • The vaccine demonstrated high effectiveness even in children vaccinated before 18 months.

Conclusions:

  • The MB JEV utilized in the NIP demonstrates high effectiveness in preventing JE.
  • The findings support continued and potentially expanded immunization efforts with MB JEV to reduce JE disease burden.